| Date | Title | Description |
| 28.12.2021 | Change of leadership at Swiss deeptech startups | |
| 08.09.2021 | U.S. FDA grants Versantis Orphan Drug Designation | Inborn errors of metabolism (IEM) causing hyperammonemia (HA) comprise a group of rare genetic metabolic diseases. A defect in an enzyme blocks the metabolic clearance of ammonia from the blood. This leads to a toxic accumulation of ammonia... |
| 17.03.2021 | Versantis celebrates successful first-in-human trial | Versantis, a clinical-stage biotech company founded by scientists from ETH Zurich and industry experts, is focused on the development of orphan drugs in liver and pediatric diseases for which today there is still a large unmet medical need.... |
| 17.03.2021 | Versantis celebrates successful first-in-human trial | |
| 11.03.2021 | New appointments at life sciences startups | Versantis AG, a clinical-stage company developing novel therapies for orphan liver diseases, appointed seasoned pharmaceutical executive Christopher Seaton to its Board of Directors. Seaton has extensive business development expertise, with... |
| 11.03.2021 | New appointments at life sciences startups | |
| 14.09.2020 | Strong Swiss delegation at Bio Europe | |
| 14.09.2020 | Strong Swiss delegation at Bio Europe | Bio Europe, Europe’s largest platform designed for companies in the biotech and pharma sectors to meet and forge partnerships. Last year, the event hosted more than 4’400 visitors from 61 countries and 2300 companies. Over 27’300 one-to-one... |
| 10.09.2020 | Cutiss leads the ranking of the Top 100 Swiss Startup Award | Within a decade, the TOP 100 Swiss Startup Award has become a benchmark in Switzerland’s startup ecosystem. This year, a selected audience of 100 startups, 100 investors, and key partners of the TOP 100 were present at the award ceremony, a... |
| 10.09.2020 | Cutiss leads the ranking of the Top 100 Swiss Startup Award | |
| 23.07.2020 | Prizes from around the world | Futurae Technologies AG, The Financial NewTech Challenge
Normal 0 false false false EN-GB X-NONE X-NONE The Financial NewTech Challenge is a global competition that aims to identify the most inspiring collaborative projects between NewTechs... |
| 23.07.2020 | Prizes from around the world | |
| 19.05.2020 | Eleven Swiss start-ups on the virtual BIO Digital stage | |
| 19.05.2020 | Eleven Swiss start-ups on the virtual BIO Digital stage | BIO International Convention has transformed into BIO Digital to bring together players in the biotech industry to exchange ideas even in times when it is impossible to gather physically. From 8 - 12 June, more than 2300 companies from all ... |
| 24.01.2020 | Venture Kick to inject 5 million Swiss francs in 80 projects | |
| 24.01.2020 | Venture Kick to inject 5 million Swiss francs in 80 projects | Venture Kick is a philanthropic initiative that provides up to CHF 150,000 in seed funding to Swiss startups in addition to a well-structured entrepreneurial path towards building a winning business. Startups pitch to expert juries at three... |
| 19.09.2019 | Daily funding roundup - September 19th, 2019 | Red Sift closed $8.8M; Robin Healthcare raised $11.5M; Tethr landed $15M; Versantis picks up $16M
NexHealth: NexHealth is a patient experience management platform helping doctors modernize the patient experience. NexHealth has raised $4.2 M... |
| 19.09.2019 | Versantis Closes CHF16M Series B Financing Round | Versantis, a Zurich, Switzerland-based clinical-stage biotech company developing therapies for rare liver and pediatric diseases, closed a CHF16m Series B financing.
The round was led by Swisscanto Invest by Zürcher Kantonalbank with partic... |
| 18.09.2019 | Versantis Raises CHF 16m to Develop its Therapies for Liver Cirrhosis and Rare Disorders | Versantis Raises CHF 16m to Develop its Therapies for Liver Cirrhosis and Rare Disorders 18.09.2019 00:00, Joseph Heaven linkedIn facebook twitter instagram youtube -->
In our interview Versantis CEO Vincent Forster reflects on his entre... |
| 18.09.2019 | Versantis Raises CHF 16m to Develop its Therapies for Liver Cirrhosis and Rare Disorders | What is Versantis' mission and core innovation?
We are committed to bring therapeutic solutions to many patients in need by timely supporting acute decompensations of liver cirrhosis (most advanced program) as well as rare urea cycle disord... |
| 18.09.2019 | Versantis obtain funds to fuel clinical trials | |
| 23.08.2019 | Versantis first drug enters clinical trials | |
| 01.04.2019 | Swiss Biotech Day to shed light on 13 emerging startups | |
| 11.09.2018 | Venturelab and digitalswitzerland present top 13 startups to international investors | |
| 05.09.2018 | Switzerland’s 100 most promising startups | |
| 17.07.2017 | Versantis receives FDA Orphan Drug Designation | |
| 19.04.2017 | 15 Swiss startups to present at Swiss Biotech Day | |
| 30.03.2017 | La farmacéutica suiza Versantis cierra una ronda de €4,1M liderada por Healthequity | 30/03/2017
VERSANTIS CIERRA UNA RONDA DE €4,1 MILLONES LIDERADA POR HEALTHEQUITY.
Versantis ha cerrado una ronda de €4,1 millones liderada por Healthequity, la sociedad de capital riesgo gestionada por el grupo financiero Riva y García y ... |
| 30.03.2017 | Versantis Raises CHF4.4M in Series A Funding Round | Versantis, a Zurich, Switzerland-based pharmaceutical company, closed a CHF4.4M Series A financing round.
The round was led by Redalpine Venture Partners with participation from Altus Partners, HealthEquity, Occident Group, Zürcher Kantonal... |
| 29.03.2017 | Versantis Raises CHF 4.4 Million in Series A Financing to Advance New Generation of Liver Disease Medicines | Versantis, a pharmaceutical company focused on the development of products addressing a high unmet medical need in the diagnosis, prevention, and treatment of liver diseases, today announces the closing of a Series A financing round of CHF ... |
| 29.03.2017 | Versantis raises CHF 4,4 million in series a financing to advance new generation of liver disease medicines |
Versantis, a pharmaceutical company focused on the development of products addressing a high unmet medical need in the diagnosis, prevention, and treatment of liver diseases, today announces the closing of a Series A financing round of CH... |
| 29.03.2017 | Versantis Raises CHF 4.4 Million in Series A Financing | |
| 29.03.2017 | Versantis Raises CHF 4.4 Million in Series A Financing to Advance New Generation of Liver Disease Medicines | Versantis Raises CHF 4.4 Million in Series A Financing to Advance New Generation of Liver Disease Medicines 29.03.2017 09:00, Lara Rossi linkedIn facebook twitter instagram youtube -->
Funding brings resources to advance lead candidate V... |
| 12.12.2016 | 18 startups selected for the Investor Summit 2017 | |
| 03.11.2016 | MassChallenge Switzerland Rewards 6 Startups and Announces Second Edition | |
| 10.10.2016 | Ten Swiss startups among the MassChallenge finalists | |
| 07.10.2016 | MassChallenge Switzerland Unveils Top 13 Startups | Those 13 startups will present to the final judging panel. Judges will have the possibility to distribute up to 1 million CHF according to the merit of the projects that will be presented. In addition, in kind support will be provided to th... |
| 02.09.2016 | Biointerfaces: Vom Labor auf den Markt | |
| 06.06.2016 | Orphan Drug Designation granted to Versantis | |
| 19.05.2016 | 51 Swiss startups in the MassChallenge 2016 Cohort | |
| 13.04.2016 | Five new CTI Startup label companies | |
| 29.01.2016 | Versantis CEO gewinnt Pfizer Forschungspreis | |
| 25.06.2015 | Remise des prix 2015 de la Fondation W.A. de Vigier | |
| 25.06.2015 | Preisverleihung 2015 der W.A. de Vigier Stiftung | |
| 10.04.2015 | 10 start-up sont en lice pour remporter 5 x CHF 100’000 | |
| 10.04.2015 | 10 Startups konkurrieren um 5 x CHF 100'000 Startkapital | |
| 24.10.2014 | CEO Day: The centre of the Swiss start-up world | |
| 23.10.2014 | Die Finalisten des Swiss Technology Award stehen fest | |
| 12.09.2014 | Western Swiss start-ups at the Swiss Exchange | |
| 29.08.2014 | Seven promising start-ups selected for next Swiss Venture Day (updated) | |
| 25.07.2014 | Volkswirtschaftsstiftung: 400‘000 Franken für Jungfirmen | |
| 08.05.2014 | >>venture>> 2014: And the winners are… | |
| 08.05.2014 | The venture leader and venture kicker L.E.S.S. wins »venture» 2014! | Yann Tissot and Simon Rivier might be the ones making the dream of flexible smartphones reality thanks to their technology providing ultra-thin and ultra-bright lighting sensors, a serious alternative to today’s LEDs. The best business plan... |
| 20.03.2014 | Swiss National Start-up Team Ready for a Trip to the US | |
| - | Versantis Announces Positive Phase 1b Results for VS-01 in Patients with Decompensated Cirrhosis | ZURICH--(BUSINESS WIRE)--Mar 17, 2021--
Versantis, a clinical-stage company developing novel therapies for orphan liver and pediatric diseases, today announced positive results from a Phase 1b clinical trial of VS-01 in decompensated liver ... |
